激酶区的故事系列丨意料之外情理之中:激酶区复制的故事
参考文献
[1]Gay LM, Pavlick D, ChungJ, et al.Genomic profiling of 114,200 advanced cancersidentifies recurrent kinase domain duplications (KDD) and oncogenicrearrangements (RE) across diverse tumor types. 2017 ESMO, Abstract:1700O.
[2] Klempner SJ,Bordoni R, Gowen K, et al.Identification of BRAF Kinase Domain DuplicationsAcross Multiple Tumor Types and Response to RAF Inhibitor Therapy[J].JAMA Oncol, 2016, 2(2): 272-274.
[3]Zehir A, Benayed R, ShahR H, et al. Mutationallandscape of metastatic cancer revealed from prospective clinical sequencing of10,000 patients [J]. Nat Med, 2017, 23(6): 703-713.
[4]WangWX, Xu CW, Zhu YC, et al. An EGFR-KDDdate in the Chinese NSCLC population and the response to EGFR-TKIs: Amulticenter study. 2018 GAP,Abstract: 4244.
[5] Plenker D, Bertrand M, de Langen AJ,et al.Structural Alterations of MET Trigger Response to METKinase Inhibition in Lung Adenocarcinoma Patients. Clin. Cancer Res, 2018, 24(6): 1337-1343.
[6] Ozer BH, Wiepz GJ, Bertics PJ. Activity and cellular localizationof an oncogenic glioblastoma multiformeassociated EGF receptor mutantpossessing a duplicated kinase domain.Oncogene, 2010, 29(6): 855-864.
[7]Baik CS, Wu D, Smith C, et al.Durable Response toTyrosine Kinase Inhibitor Therapy in a Lung Cancer Patient Harboring EpidermalGrowth Factor Receptor Tandem Kinase Domain Duplication[J].J Thorac Oncol, 2015, 10(10): e97-99.
[8]Gallant JN, Sheehan JH, Shaver TM, et al. EGFR KinaseDomain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer ThatIs Clinically Responsive to Afatinib. Cancer Discov, 2015,5(11): 1155-1163.
[9] Kemper K, KrijgsmanO, Kong X,etal. BRAF(V600E) Kinase DomainDuplication Identified in Therapy-Refractory Melanoma Patient-DerivedXenografts.CellRep, 2016, 16(1): 263-277.